Navigation Links
BiondVax Begins Phase IIa Study for Universal Flu Vaccine

BiondVax Begins Phase IIa Study for Universal Flu Vaccine -- NESS ZIONA, Israel, Oct. 11 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

BiondVax Begins Phase IIa Study for Universal Flu Vaccine


NESS ZIONA, Israel, Oct. 11 /PRNewswire-FirstCall/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.  The vaccine is comprised of a unique, proprietary combination of conserved epitopes from influenza virus proteins, designed to stimulate both humoral (antibody-mediated) and cell-mediated immunity against both Type A and Type B influenza strains, and is thereby intended to provide protection against all seasonal and pandemic flu strains.

The Phase IIa study is a randomized, double-blind, placebo-controlled, multi-center, safety and immunogenicity study in 200 healthy volunteers.  The study is being conducted at two clinical research centers in Israel, the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem ("Hadassah") and the Tel Aviv Sourasky Medical Center ("Ichilov").  The principal investigators conducting the clinical trial are Prof. Yoseph Caraco, Director of the Clinical Research Center at Hadassah and Dr. Jacob Atsmon, Director of the Clinical Research Center at Ichilov.

Dr. Ron Babecoff, BiondVax's President and CEO, said, "The commencement of this Phase IIa study is a major milestone in the clinical development of the Multimeric-001 universal influenza vaccine.  After the excellent results we achieved in our two previous Phase I/II trials, in which the Multimeric-001 vaccine was shown to be safe and immunogenic in both younger and older adults, we are excited to be embarking on this new important phase in the development of the universal influenza vaccine."

In the study, a total of 200 subjects, both male and female, 18-49 years old, will be divided into six groups, enabling the assessment of the safety and immunogenicity of the Multimeric-001 firstly as a standalone vaccine, secondly as a primer for a subsequent partial dose of a commercially available trivalent inactivated vaccine (TIV), and lastly when the Multimeric-001 vaccine is co-administered together with a TIV.

Participants in the first group will receive two 500 microgram doses of an adjuvanted formulation of the Multimeric-001 vaccine (the formulation that performed best in the previous Phase I/II trials), 21 days apart.  These participants will then receive a subsequent partial (15%) dose of a TIV, 60 days after their second immunization.  Participants in this treatment group will be compared against two control groups: one group that will receive two administrations of placebo 21 days apart, also followed 60 days later by a partial (15%) dose of TIV, and another group that will only receive two administrations of adjuvanted placebo, 21 days apart.  

Participants in the fourth and fifth groups will receive a single 500 microgram dose of the adjuvanted formulation of the Multimeric-001 vaccine, co-administered with either a 15% or 50% dose of the TIV, respectively.  These groups will be compared against a control group that will receive a placebo formulation co-administered with the higher of the two TIV doses.

The primary objectives of the Phase IIa study are to assess safety and immunogenicity, as measured by the level of IgG antibodies to the Multimeric-001 vaccine.  The secondary objectives of the study are to measure additional antibody and cellular immune responses, in particular neutralization by complement, Hemagglutination inhibition (HI) responses (a measure of protection) against various strains of influenza, as well as proliferation of Interleukin-2 (IL-2) and Interferon-gamma cytokines.  The company expects to report study results by mid-2011.For further information, please contact:Danny Aronovic
Public Relations Consultant
shapira marketing

Tel: +972 9 899 5813
Mob: +972 50 799 1121 About BiondVax Pharmaceuticals Ltd.BiondVax Pharmaceuticals ("the Company"), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza ("flu") Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against all human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.

BiondVax's proprietary technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

BiondVax has successfully concluded two Phase I/II trials in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic.  The Company is now conducting a Phase IIa study, expected to be completed by mid-2011.

For further information on BiondVax, please visit

SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
2. LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner
3. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
4. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
5. Sysmex America Begins Distribution of CellaVision® DM1200
6. Renhuang Begins Trading on NYSE Amex
7. Par Pharmaceutical Begins Shipment of Generic Zegerid®
8. Curemark Begins Autism Trials at Two More Sites
9. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
10. The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available
11. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership ... PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0 ... analytics and visualization platform that helps radiologists detect, diagnose ... 2015 Radiological Society of North America Annual Meeting ... IntelliSpace Portal 8.0 helps address the changing demands in ...
(Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
(Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The American Society for Clinical Pathology (ASCP) announced today that ... On Nov. 30, ASCP shared its “Give a minute. Get tested. Find a cure.” ... importance of getting tested for HIV. , ASCP has asked members to replace their ...
(Date:11/30/2015)... Beach, FL (PRWEB) , ... November 30, 2015 ... ... of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer ... and even more so for a child’s exposure limits. , The original Nov ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... scoop often results in wasted time. Fortunately, an inventor from Chesterfield, Va., has found ... SCOOP CLIP to keep the scoop used to measure powdered contents in a canister ...
(Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... its industry-leading suite of automated breast density assessment and enterprise analytics solutions, ... November 29-December 4, 2015 (South Hall booth #2377). Volpara’s quantitative breast imaging ...
Breaking Medicine News(10 mins):